ALEC Quote, Financials, Valuation and Earnings

Geron has a net margin of -3.82% compared to Alector's net margin of -53.33%. Alector's return on equity of -83.91% beat Geron's return on equity of -59.29%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 331.65%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 262.9%. Given that Alector has higher upside potential than Geron, analysts believe Alector is more attractive than Geron.

Alector has a beta of 0.736, which suggesting that the stock is 26.435% less volatile than S&P 500. In comparison Geron has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.916%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are larger than Geron quarterly revenues of $47.5M. Alector's net income of -$2.1M is higher than Geron's net income of -$25.4M. Notably, Alector's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.94x versus 10.40x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -3.82% compared to Alector's net margin of -57.51%. Alector's return on equity of -83.91% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 331.65%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 34.53%. Given that Alector has higher upside potential than Madrigal Pharmaceuticals, analysts believe Alector is more attractive than Madrigal Pharmaceuticals.

Alector has a beta of 0.736, which suggesting that the stock is 26.435% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Alector's net income of -$2.1M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Alector's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.94x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -3.82% compared to Alector's net margin of -103.5%. Alector's return on equity of -83.91% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 331.65%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $78.33 which suggests that it could grow by 27.7%. Given that Alector has higher upside potential than Rhythm Pharmaceuticals, analysts believe Alector is more attractive than Rhythm Pharmaceuticals.

Alector has a beta of 0.736, which suggesting that the stock is 26.435% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.321, suggesting its more volatile than the S&P 500 by 132.096%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Alector's net income of -$2.1M is higher than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Alector's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.94x versus 28.75x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -3.82% compared to Alector's net margin of 40.94%. Alector's return on equity of -83.91% beat United Therapeutics's return on equity of 20.21%.

Alector has a consensus price target of $4.22, signalling upside risk potential of 331.65%. On the other hand United Therapeutics has an analysts' consensus of $400.48 which suggests that it could grow by 40.43%. Given that Alector has higher upside potential than United Therapeutics, analysts believe Alector is more attractive than United Therapeutics.

Alector has a beta of 0.736, which suggesting that the stock is 26.435% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.632, suggesting its less volatile than the S&P 500 by 36.833%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Alector quarterly revenues are $54.2M, which are smaller than United Therapeutics quarterly revenues of $735.9M. Alector's net income of -$2.1M is lower than United Therapeutics's net income of $301.3M. Notably, Alector's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 11.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 0.94x versus 4.81x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.